The effect of syndrome X on the development of cardiovascular pathology (review of literature)
Metabolic syndrome, also known as syndrome X, is defined by WHO as a pathological condition characterized by abdominal obesity, insulin resistance, hypertension and hyperlipidemia. While there are some differences in definitions adopted by other health organizations, the differences are minor. Successfully defeating infectious diseases, this new noncommunicable disease has become a leading cause of morbidity and mortality not only in the developed world, but also in underdeveloped countries. As highlighted in the literature, multiple factors such as obesity, abnormal lipid profiles and insulin resistance play a key role in the onset of cardiovascular disease. In this brief review, we present an updated hypothesis that insulin resistance and compensatory hyperinsulinemia are major factors in elevated blood pressure in metabolic syndrome and obesity. Obesity is a worldwide epidemic closely linked to the development of type 2 diabetes and CVD. Obesity-related visceral and epicardial obesity are the main causes of heart disease in these individuals. Obesity has a major impact on changes in blood pressure, lipid profile, and factors associated with systemic and vascular inflammation, as well as endothelial dysfunction.
Chupakha M.V., Belousova O.N., Kochinova E.A. 2020. Influence of syndrome X on the development of cardiovascular pathology. Challenges in Modern Medicine, 43 (4): 498–508 (in Russian). DOI: 10.18413/2687-0940-2020-43-4-498-508
While nobody left any comments to this publication.
You can be first.
Babenko A.Ju., Matveev G.A., Alekseenko T.I., Derevickij I.V., Kokina M.A., Shljahto E.V. 2019. Vzaimosvjazi komponentov metabolicheskogo sindroma s urovnem gormonov, vovlechennyh v reguljaciju metabolizma zhirovoj tkani [The relationship of the components of the metabolic syndrome with the level of hormones involved in the regulation of the metabolism of adipose tissue]. Arterial'naja gipertenzija. 25 (6): 639–652. doi:10.18705/1607-419X-2019-25-6-639-652 (in Russian).
Belousova O.N., Koroleva M.V., Il'nickij A.N., Kudashkina E.V., Korshun E.I., Sharova A.A., Kuksova T.V. 2019. Kompleksnaja kognitivnaja reabilitacija pozhilyh pacientov s metabolicheskim sindromom [Complex cognitive rehabilitation elderly patients with metabolic syndrome]. Sovremennye problemy zdravoohranenija i medicinskoj statistiki. 4: 151–167 (in Russian).
Belousova O.N., Satardinova Je.E., Shamaraeva I.V., Paranovich A.A., Gurko G.I. 2017. Plejotropnye jeffekty metabolicheskoj terapii [Pleiotropic effects of metabolic therapy. Modern problems of science and education: electron]. Sovremennye problemy nauki i obrazovanija: jelektron. nauch. zhurn. 6. Rezhim dostupa: https://science-education.ru/ru/article/view?id=27061 (in Russian).
Osipova O.A., Nagibina A.I., Komisov A.A., Petrova G.D. 2016. Patomorfologicheskie mehanizmy reguljacii obrazovanija miokardial'nogo fibroza u bol'nyh hronicheskoj serdechnoj nedostatochnost'ju na fone ishemicheskoj bolezni serdca [Pathomorphological mechanisms of regulation of the formation of myocardial fibrosis in patients with chronic heart failure on the background of ischemic heart disease]. Zhurnal serdechnaja nedostatochnost'. 17 - 5 (98): 357–364 (in Russian).
Rotar' O.P., Kolesova E.P., Moguchaja E.V., Bojarinova M.A., Hromova N.V., Alieva A.S., Vasil'eva E.Ju., Beljaeva O.D., Bazhenova E.A., Baranova E.I., Cherepanova N.A., Dupljakov D.V.‚ Libis R.A., Basyrova I.R., Lopina E.A., Dushina A.G., Solncev V.N., Kostareva A.A., Konradi A.O., Shljahto E.V. 2019. Geneticheskie markery metabolicheskogo sindroma v rossijskoj populjacii [Genetic markers of metabolic syndrome in the Russian population] (po materialam issledovanija JeSSE-RF). Arterial'naja gipertenzija. 25 (5): 467–477. doi:10.18705/1607-419X-2019-25-5-467-477 (in Russian).
Chernina V.Ju., Morozov S.P., Nizovcova L.A., Blohin I.A., Sitdikov D.I., Gombolevskij V.A. 2019. Rol' kolichestvennoj ocenki visceral'noj zhirovoj tkani serdca kak prediktora razvitija serdechno-sosudistyh sobytij [The role of quantitative assessment of the visceral adipose tissue of the heart as a predictor of the development of cardiovascular events. Bulletin of radiology and radiology]. Vestnik rentgenologii i radiologii. 100 (6): 387–94 (in Russian).
Chesnikova A.I., Batjushin M.M., Terent'ev V.P. 2016. Arterial'naja gipertenzija i komorbidnost': sovremennoe sostojanie problem [Arterial hypertension and comorbidity: current state of the problem]. Arterial'naja gipertenzija. 22 (5): 432–440. doi: 10.18705/1607-419X-2016-22-5-432-440 (in Russian).
Chen C., Kassan A., Castañeda D., Gabani M., Choi S.K., Kassan M. 2019. Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway. Hypertens. Res. 42 (7): 960-969. doi: 10.1038/s41440-019-0212-z. Epub Jan 21. PMID: 30664704; PMCID: PMC6571038.
Chen D.L., Liess C., Poljak A., Xu A., Zhang J., Thoma C., Trenell M., Milner B., Jenkins A.B., Chisholm D.J., Samocha-Bonet D., Greenfield J.R. 2015. Phenotypic characterization of insulinresistant and insulin-sensitive obesity. J. Clin. Endocrinol. Metab., 100: 4082–4091. 10. Ciccone M.M., Cortese F., Gesualdo M., Donvito I., Carbonara S., De Pergola G. 2016. A glycemic threshold of 90 mg/dl promotes early signs of atherosclerosis in apparetly healthy over-weight/obese subjects. Endocr. Metab. Immune. Disord. Drug. Targets. 16 (4): 288–295. doi: 10.2174/1871530317666161205124955.
Da Silva A.A., do Carmo J.M., Li X., Wang Z., Mouton A.J., Hall J.E. 2020. Role of Hyper-insulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. Can. J. Cardiol. 36 (5): 671–682. doi: 10.1016/j.cjca.2020.02.066. Epub 2020 Feb 12. PMID: 32389340; PMCID: PMC7219403.
Dai S., Huang B., Zou Y., Liu Y. 2019. Associations of dipping and non-dipping hypertension with cardiovascular diseases in patients with dyslipidemia Arch. Med. Sci., 15: 337–342.
Dinesh Shah A., Langenberg C., Rapsomaniki E., Denaxas S., Pujades-Rodriguez M., Gale C.P., Deanfield J., Smeeth L., Timmis A., Hemingway H. 2015. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. Lancet. 385 (1): 86. doi: 10.1016/S0140-6736(15)60401-9.
Ferrannini E., Haffner S.M., Stern M.P. 1990. Essential hypertension: an insulin-resistant state J. Cardiovasc. Pharmacol., 15 (5): 18–25.
Gast K.B., Tjeerdema N., Stijnen T., Smit J.W., Dekkers O.M. 2012. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE. 7 (12): 52036. doi: 10.1371/journal.pone.0052036.
Hamidi Shishavan M., Henning R.H., van Buiten A., Goris M., Deelman L.E., Buikema H. 2017. Metformin improves endothelial function and reduces blood pressure in diabetic spontaneously hypertensive rats independent from glycemia control: comparison to vildagliptin. Sci Rep. 7: 10975.
Kaplan N.M. 1989. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension Arch. Intern. Med., 149: 1514–1520.
Meyer M.L., Gotman N.M., Soliman E.Z., Whitsel E.A., Arens R., Cai J., Daviglus M.L., Denes P., Gonzalez H.M., Moreiras J. 2016. Association of glucose homeostasis measures with heart ratevariability among Hispanic/Latino adults without diabetes: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Cardiovasc Diabetol. 15: 45. doi: 10.1186/s12933-016-0364-y.
Neeland I.J., Poirier P., Despres J.P. 2018. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management Circulation, 137: 1391–1406.
Ogurtsova K., Fernandes J.D., Huang Y. 2017. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes research and clinical practice. 128: 40–50. doi: 10.1016/j.diabres.2017.03.024.
Ormazabal V., Nair S., Elfeky O., Aguayo C., Salomon C., Zuñiga F.A. 2018. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 31; 17 (1): 122. doi: 10.1186/s12933-018-0762-4. PMID: 30170598; PMCID: PMC6119242.
Reaven G.M. 1994. Syndrome X: 6 years later. J. Intern. Med. Suppl., 736: 13–22.
Saklayen M.G. 2018. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 20 (2): 12. doi: 10.1007/s11906-018-0812-z. PMID: 29480368; PMCID: PMC5866840.
Singer P. 1977. Diagnosis of primary hyperlipoproteinemias. Gesamte. Inn. Med., 32: 129–133.
Westergren H.U., Svedlund S., Momo R.A., Blomster J.I., Wahlander K., Rehnstrom E., Greasley P.J., Fritsche-Danielson R., Oscarsson J., Gan L.M. 2016. Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects. Cardiovasc. Diabetol. 15: 36. doi: 10.1186/s12933-016-0353-1.
Zhou J., Massey S., Story D., Li L. 2018. Metformin: An Old Drug with New Applications. Int. J. Mol. Sci. 19 (10): 2863. doi: 10.3390/ijms19102863. PMID: 30241400; PMCID: PMC6213209.
Zhou L., Liu H., Wen X., Peng Y., Tian Y., Zhao L. 2017. Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials. J. Hypertens. 35: 18–26.